The latest news round up for trade-able items on the First Global Credit platform, covering:
- Biogen Idec
- Clovis Oncology
- Dunkin Brands
Apple, Inc (NASDAQ:AAPL)
The stock price of Apple Inc. (NASDAQ:AAPL) could increase 43% over the next 12 months, according to Goldman Sachs, which also added the stock to its “conviction buy list.”
The investment bank set a $163 price target on the shares of Apple. The stock closed $117.29 per share on Wednesday, up by more than 3% driven by Goldman Sachs bullish conviction in the iPhone maker.
In a note to investors, Goldman Sachs said Apple’s stock is currently trading at 11 times price-to-earnings ratio (P/E), similar to a “hardware stock.” However, the investment bank noted that Apple is introducing different services such as the Apple Music, and it believes that the iPhone maker is becoming more similar to Facebook (NASDAQ:FB) or Alphabet Inc’s (NASDAQ:GOOG) (NASDAQ:GOOGL) Google.
“Apple’s multiple embodies the scars from prior fallen giants in hardware (Motorola, Nokia, BlackBerry, and HP, to name a few). However, we think Apple’s business model has less in common with traditional hardware companies, and more in common with companies that monetize mobile users through content and services,” wrote Goldman Sachs.
For more go to: http://www.opptrends.com/2015/11/apple-inc-aapl-goldman-sachs/
Biogen Idec, Inc (NASDAQ:BIIB)
Vetr upgraded shares of Biogen (NASDAQ:BIIB) from a buy rating to a strong-buy rating in a research report report published on Monday morning. They currently have $318.10 target price on the biotechnology company’s stock.
A number of other equities analysts have also weighed in on the company. Cowen and Company reiterated a buy rating and set a $494.00 price objective on shares of Biogen in a research report on Wednesday, July 22nd. Oppenheimer restated a sector perform rating on shares of Biogen in a research report on Wednesday, September 23rd. Zacks Investment Research cut Biogen from a hold rating to a sell rating in a report on Thursday, October 1st. Piper Jaffray restated an overweight rating and issued a $410.00 target price (down previously from $485.00) on shares of Biogen in a research note on Tuesday, July 21st.
Finally, Leerink Swann reduced their price objective on Biogen from $464.00 to $425.00 and set an outperform rating for the company in a research report on Tuesday, September 15th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $398.96.
Bitcoin is trading flat again and the trading range that began on November 13th is still in force. For the past five days now BTC/USD oscillated up and down but ultimately ended back at the $330 figure. We are currently quoted at $331.71 on BTC-E, with the daily range shrinking to only $5.99 dollars.
The BTC-E discount to the general USD market is now within the normal $2-$3 dollars seen before the October rally. The premium on Chinese exchanges over USD sites has disappeared as well, with most quoting BTC at 2,131 Yuan or $335.71 dollars. This page provides an overview of all major BTC exchanges.
The normalization of the premium/discount across exchanges is yet another signal that calmer markets may follow. During the month-long rally that ended on November 11th, exchanges were moving all over the place due to the large volatility. Other indicators show a noticeable slowdown as well. The 14-day Average True Range has plummeted from a high of $41.85 dollars on November 15th to $24.57 dollars today. This is still high by historical standards, the values before the October rally ranged between $4-$5 dollars.
Clovis Oncology (NASDAQ:CLVS)
Clovis Oncology was upgraded by analysts at Vetr from a “hold” rating to a “strong-buy” rating in a research report issued on Monday. The brokerage presently has a $54.87 target price on the biopharmaceutical company’s stock. Vetr‘s target price would suggest a potential upside of 103.30% from the stock’s previous close.
Shares of Clovis Oncology traded up 0.67% during mid-day trading on Monday, reaching $26.99. The company had a trading volume of 3,764,340 shares. The firm has a 50-day moving average of $93.07 and a 200-day moving average of $88.45. The company’s market capitalization is $1.03 billion. Clovis Oncology has a 12-month low of $26.02 and a 12-month high of $116.75.
Clovis Oncology last announced its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($2.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.07) by $0.55. During the same quarter last year, the company earned ($1.17) EPS. On average, equities analysts anticipate that Clovis Oncology will post ($9.16) earnings per share for the current fiscal year.
Dunkin Brands Group, Inc (NASDAQ:DNKN)
Dunkin Brands Group was upgraded by Vetr from a “buy” rating to a “strong-buy” rating in a research note issued on Monday. The brokerage presently has a $45.62 price objective on the stock. Vetr‘s price objective indicates a potential upside of 11.02% from the company’s previous close.
Shares of Dunkin Brands Group traded up 0.29% on Monday, reaching $41.09. 993,178 shares of the company’s stock traded hands. The firm has a market cap of $3.81 billion and a P/E ratio of 24.80. The stock has a 50-day moving average of $42.11 and a 200 day moving average of $49.67. Dunkin Brands Group has a 12-month low of $39.29 and a 12-month high of $56.79.
Dunkin Brands Group last released its quarterly earnings data on Thursday, October 22nd. The company reported $0.52 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.51 by $0.01. The business earned $209.80 million during the quarter, compared to analysts’ expectations of $204.32 million. During the same period last year, the company earned $0.49 earnings per share. The firm’s revenue was up 8.9% compared to the same quarter last year. On average, equities research analysts expect that Dunkin Brands Group will post $1.91 earnings per share for the current year.
LinkedIn, Corp (NYSE:LNKD)
LinkedIn Corporation shares are expected to touch $271.17 in the short term. This short term price target has been shared by 24 analysts. However, the standard deviation of short term price estimate has been valued at 32.78. The target price could hit $310 on the higher end and $189 on the lower end.
For the current week, the company shares have a recommendation consensus of Buy. Many analysts have commented on the company rating. Equity analysts at the Brokerage firm Barclays maintains its rating on LinkedIn Corporation (NYSE:LNKD). The rating major has initiated the coverage with an overweight rating on the shares. The Analysts at Barclays raises the price target from $250 per share to $265 per share. The rating by the firm was issued on November 2, 2015.
LinkedIn Corporation has dropped 1.37% in the last five trading days, however, the shares have posted positive gains of 25.89% in the last 4 weeks. LinkedIn Corporation is up 37.76% in the last 3-month period. Year-to-Date the stock performance stands at 8.29%.
Netflix, Inc (NASDAQ:NFLX)
Netflix had its target price raised by Citigroup Inc. from $110.00 to $121.00 in a research report sent to investors on Friday.
In related news, insider Jonathan Friedland sold 3,213 shares of the stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $105.09, for a total transaction of $337,654.17. The transaction was disclosed in a filing with the Securities & Exchange Commission. Also, Director A George Battle sold 49,000 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $107.95, for a total value of $5,289,550.00.
Shares of Netflix traded up 3.01% on Friday, hitting $120.63. 23,353,565 shares of the company traded hands. Netflix has a 12 month low of $45.08 and a 12 month high of $129.29. The company has a market capitalization of $51.56 billion and a PE ratio of 320.82. The stock’s 50-day moving average price is $107.22 and its 200-day moving average price is $102.2
Visa, Inc (NYSE:V)
Visa was downgraded by Vetr from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday. They currently have a $82.38 target price on the credit-card processor’s stock. Vetr‘s price target would suggest a potential upside of 2.39% from the stock’s previous close.
Visa traded up 2.07% during midday trading on Wednesday, hitting $80.46. The stock had a trading volume of 7,212,397 shares. The company has a 50-day moving average of $76.13 and a 200-day moving average of $71.79. The stock has a market cap of $195.83 billion and a price-to-earnings ratio of 30.95. Visa has a 1-year low of $60.00 and a 1-year high of $80.50.
Visa last issued its quarterly earnings results on Monday, November 2nd. The credit-card processor reported $0.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.63 by $0.01. The company earned $3.60 billion during the quarter, compared to analyst estimates of $3.56 billion. During the same period in the prior year, the business posted $2.18 EPS. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. Equities research analysts forecast that Visa will post $2.88 EPS for the current year.